BC Business
GOOD RUN Cardiome Pharma Corp. TSX:COM +70% (September) Vancouver’s battered former biotech darling picked itself off the mat in September thanks to some welcome good news. The company had been trading around the $2 level since losing a partnership with pharma giant Merck and laying off most of its staff in 2012. This summer its strategy to pursue smaller partnerships began to pay off with agreements to market its Brinavess atrial fibrillation treatment in select European countries as well as Israel.BAD RUN Carmanah Technologies Corp. TSX:CMH -11% (September) The bad news keeps on coming for the maker of solar-powered lighting products. In September Carmanah announced its previous projections of revenue growth and positive cash flow were overly optimistic, as were its continually revised completion dates for a significant sale in South America. In September CFO Roland Sartorius left and Carmanah was also targeted in a lawsuit claiming patent infringement. •